New arthritis drug trial seeks to tame Treatment-Resistant disease
NCT ID NCT07423533
Summary
This study is testing whether a new injectable medication called GenSci120 can help control rheumatoid arthritis in people whose current treatments aren't working well enough. Researchers will compare different doses of GenSci120 against a placebo and an existing arthritis drug (adalimumab) in 450 participants over several months. The goal is to see if GenSci120 reduces joint pain, swelling, and disease activity better than current options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.